LUNG CANCER

For the treatment of patients with lung cancer and low PD-L1 expression, immunotherapy-based combinations have been shown effective through clinical trial research. Stephen Liu, MD, reviewed the studies during a Targeted Oncology Case-Based Peer Perspectives virtual event.

The FDA has approved trilaciclib (Cosela) as a first-in-class agent to help reduce the frequency of chemotherapy-induced bone marrow suppression in adults receiving chemotherapy for extensive-stage small cell lung cancer.

Kartik Konduri, MD, comments on the future of treating extensive-stage small cell lung cancer and provides advice for community oncologists treating patients with the disease.

Kartik Konduri, MD, describes the phase 2 basket trial of lurbinectedin in the treatment of extensive-stage small cell lung cancer.

Kartik Konduri, MD, discusses treatment options for extensive-stage small cell lung cancer.

Kartik Konduri, MD, evaluates the case of a 68-year-old woman with extensive-stage small cell lung cancer.

Kartik Konduri, MD, reviews the case of a 68-year-old woman with small-cell lung cancer.

The combination of osimertinib and selpercatinib was found to be an active regimen in patients with EGFR-positive non–small cell lung cancer with acquired RET fusions.

During a Targeted Oncology Case-Based Peer Perspectives event, Todd Bauer, MD, medical oncologist, Tennessee Oncology, discussed the results from clinical trials that include patients with RET-altered lung cancer to determine a treatment strategy for a 59-year-old patient.

The FDA has granted an accelerated approval to tepotinib for the treatment of adult patients with metastatic non–small cell lung cancer who harbor a MET exon 14 skipping alteration.

Brendon Stiles, MD, discusses the current landscape for treating patients with metastatic lung cancer.

Patient-reported outcomes outcomes from the Check-Mate 743 trial demonstrated improved symptom burden and maintained overall health status with the use of nivolumab/ipilimumab over chemotherapy, in patients with unresectable malignant pleural mesothelioma.

Significantly more genomic alterations can be detected with the Guardant360 liquid biopsy assay when used prior to tissue testing, results of a prospective study recently showed.

Treatment with the next-generation ROS1 and TRK tyrosine kinase inhibitor repotrectinib is sustaining good objective responses and is tolerable in patients with ROS1 fusion–positive non–small cell lung cancer, according to updated preliminary results from the phase 2 expansion 1 cohort of the ongoing phase 1/2 TRIDENT-1 clinical trial.

The combination of atezolizuma plus carboplatin and etoposide demonstrated improvement in overall survival and progression-free survival when given as maintenance therapy to patients extensive stage small cell lung cancer, according to the latest findings from the IMpower 133 trial.

In the phase 3 VISION study, treatment with the MET inhibitor, tepotinib showed durable clinical activity as treatment of patients with MET exon 14 skipping non‒small cell lung cancer.

Patritumab deruxtecan demonstrated early and clinically meaningful activity in pretreated patients with metastatic or unresectable EGFR-mutant non–small cell lung cancer in the results of a phase 1 trial that were presented during the International Association for the Study of Lung Cancer 2020 World Conference on Lung Cancer Singapore.

Datopotamab deruxtecan showed antitumor activity in the treatment of patients with advanced or metastatic non–small cell lung cancer, according to updated results of the phase 1 TROPION-PanTumor01 trial.

Patient-reported outcomes from the phase 3 ADAURA trial showed that adjuvant osimertinib maintained health-related quality of life compared with placebo in patients with EGFR-positive non–small cell lung cancer.

Mobocertinib induced responses among patients with metastatic non–small cell lung cancer who have EGFR exon 20 insertion mutations and previously treated disease, according to findings from a phase 1/2 trial.

Survival was not improved with the immunotherapy combination of pembrolizumab and ipilimumab in comparison with pembrolizumab monotherapy in the first-line treatment of patients with metastatic non–small cell lung cancer who had high PD-L1 expression and did not harbor EGFR or ALK aberrations, findings from the phase 3 KEYNOTE-598 trial showed.

Neoadjuvant atezolizumab followed by surgery led to a major pathologic response in 21% of patients with resectable stage IB-IIIB non–small cell lung cancer, according to findings from the primary analysis of the LCMC3 trial.

Nivolumab is an effective treatment approach for patients with previously treated malignant mesothelioma according to data from the phase 3 CONFIRM trial.

Luis E. Raez, MD, discusses the treatment of TRK fusion-positive lung cancers in the past and the present.

One retrospective study from Spain quantified the impact the COVID-19 pandemic has had in 2020 on lung cancer diagnosis and prognosis.

In patients with EGFR-mutated non–small cell lung cancer, adjuvant treatment with osimertinib in the pivotal phase 3 ADAURA trial led to improvement in disease-free survival, irrespective of previous adjuvant chemotherapy received or disease stage.

Lyudmila A. Bazhenova, MD, explains the impact of having larotrectinib results in a lung cancer cohort, as seen in a presentation of data from 14 patients, given during the 2020 World Conference on Lung Cancer Singapore.

Antitumor activity was demonstrated with trastuzumab deruxtecan treatment in patients with HER2-overexpressing non–small cell lung cancer, regardless of HER2 expression levels, according to interim findings from a cohort of the phase 2 DESTINY Lung-01 trial.

Progression-free survival and overall survival benefits, combined with a higher objective response rate, confirmed the noninferiority of nab-paclitaxel compared with docetaxel in previously treated patients with advanced non–small cell lung cancer, according to phase 3 trial results.

Antitumor activity was seen in the combination of pembrolizumab plus concurrent chemoradiation therapy in patients with unresectable, locally advanced, stage III non-small cell lung cancer, regardless of PD-L1 status or tumor histology.